Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12977550 | 0.88 | PTGS2 (0.36) | KDM4ETDP1ALDH1A1POLBTHRB | |
| SCHEMBL12977563 | 0.80 | PTGS2 (0.37) | KDM4ETDP1ALDH1A1POLBTHRB | |
| SCHEMBL13382183 | 0.69 | MEN1 (0.33) | MEN1ALDH1A1KMT2A | |
| SCHEMBL16213757 | 0.67 | RAB9A (0.39) | KDM4ETDP1MEN1ALDH1A1KMT2A | |
| SCHEMBL13377490 | 0.64 | HPGD (0.32) | — | |
| SCHEMBL12977543 | 0.60 | ADRA2C (0.37) | KDM4ETDP1MEN1ALDH1A1KMT2A | |
| SCHEMBL13002584 | 0.59 | HTT (0.39) | ALDH1A1LMNA | |
| SCHEMBL15834887 | 0.58 | HPGD (0.37) | KDM4ETDP1MEN1ALDH1A1KMT2A | |
| SCHEMBL15501032 | 0.58 | ARG1 (0.33) | — | |
| SCHEMBL11335439 | 0.57 | HTR2A (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090148382-A1 | Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20080025915-A1 | Technetium-And Rhenium-Bis (Heteroaryl) Complexes, And Methods Of Use Thereof | CITIZENS BANK, N.A. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148382-A1 | Technetium- and rhenium-bis(heteroaryl) complexes, and methods of use thereof | QPCT, SLC7A5, RAB35 | KDM4E 2670/4885TDP1 3103/4885MEN1 92/4885 |
| US-20080025915-A1 | Technetium-And Rhenium-Bis (Heteroaryl) Complexes, And Methods Of Use Thereof | SLC7A5, RAB35, AADAT | KDM4E 1882/4885TDP1 2995/4885MEN1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.